Bristol-Myers Squibb BMY Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:ReceivablesNetCurrent.
The official record: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's accounts receivable?
- Bristol-Myers Squibb (BMY) reported accounts receivable of $10.55B in Q2 2026.
- How has Bristol-Myers Squibb's accounts receivable changed year-over-year?
- Bristol-Myers Squibb's accounts receivable decreased by 7.6% year-over-year, from $11.42B to $10.55B.
- What is the long-term trend for Bristol-Myers Squibb's accounts receivable?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's accounts receivable has grown at a 6.1% compound annual growth rate (CAGR), from $8.5B to $11.41B.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.